on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Announces Cash Position and Business Updates
On July 8, 2026, GenSight Biologics reported a cash position of €1.7 million as of June 30, 2026. This marks a decrease from €3.2 million at the end of March. The reduction is attributed to operating cash burn related to GS010/LUMEVOQ® Early Access Programs and preparation for the Phase III RECOVER study for Leber Hereditary Optic Neuropathy (LHON).
In the first half of 2026, GenSight collected €6.8 million from early access programs, including €4.3 million in the second quarter. The company expects additional treatments through these programs globally this year.
Manufacturing processes for GS010/LUMEVOQ® have been optimized at Catalent, with confirmatory tests in progress. GenSight anticipates manufacturing more batches post-confirmation. The organization reinforced its Quality and CMC departments, with plans to enhance the clinical team.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news